Westfield Capital Management
PRAX icon

Westfield Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Westfield Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.3M Buy
218,898
+218,236
+32,966% +$69.1M 0.24% 120
2026
Q1 		$213K Buy
+662
New +$205K ﹤0.01% 248

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Westfield Capital Management's PRAX Position: Q2 2026 in Review

Westfield Capital Management increased its Praxis Precision Medicines (PRAX) stake by 32,966% in Q2 2026, buying an estimated $69.1M and bringing the position to 218,898 shares worth $73.3M. The position accounts for 0.24% of the portfolio, ranked #120.

Westfield Capital Management first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Westfield Capital Management held 218,898 shares of Praxis Precision Medicines worth $73.3M as of Q2 2026.
  • Westfield Capital Management bought 218,236 Praxis Precision Medicines shares in Q2 2026, an estimated $69.1M.
  • Praxis Precision Medicines made up 0.24% of Westfield Capital Management's portfolio in Q2 2026, its #120 holding.
  • Westfield Capital Management first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.